Gilead recruits Terray in AI-driven drug discovery pact
Gilead Sciences has tapped the artificial intelligence (AI) specialist Terray Therapeutics to co-develop drugs for undisclosed disease targets in a drug discovery collaboration
Clinical evolution
AbbVie acquires Roche immune drug spinout in $200 million deal
The acquisition of Nimble Therapeutics will grant AbbVie access to a pipeline of oral peptide drugs for the treatment of immune diseases including psoriasis and inflammatory bowel disease
Nintx bags $10 million to fuel develop plant-based therapies from Amazon rainforest
The plant-based drug specialist Nintx has raised $10 million in an “unprecedented” Series A round for Brazil’s pharmaceutical sector
Noema Pharma raises $147 million to develop drugs for neurological conditions
The fundraising will support four clinical trials evaluating three drug candidates for the treatment of a series of disorders that affect the central nervous system
AbbVie’s Parkinson’s disease monotherapy achieves positive phase 3 results
AbbVie: There is an unmet need for efficient treatments for Parkinson’s disease
AstraZeneca doubles down on US manufacturing with $3.5 billion investment
AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it unveils a $3.5 billion infusion into US sites.
Overcoming nonspecific binding challenges in pharmacokinetic assays
Pharmacokinetic (PK) tests form an integral part of the drug development process, helping to ensure the safety and efficacy of new drugs.
Transparency and remote options key in clinical trial engagement
A recent Lindus Health survey emphasizes the importance of patient-centered designs in clinical trials, particularly highlighting how telehealth options could improve accessibility and convenience for participants.
Jennifer Visser-Rogers: Leading science transformation at Coronado Research
In a conversation with Professor Jennifer Visser-Rogers, chief scientific officer at Coronado Research, she shares insights on the evolving landscape of pharmaceutical development.
Senhwa Biosciences starts trial of silmitasertib in children with difficult to treat cancers
The Taiwanese biotech has launched a phase 1/2 trial to test its small molecule cancer therapy in children and young adults with relapsed or treatment resistant tumors.
Competitors race to launch GLP-1 drugs amid soaring weight loss demand
Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are the companies racing for approval of their own versions of these highly coveted drugs.
GSK beefs up US manufacturing site with $800 million investment
The big pharma company GlaxoSmithKline will inject up to $800 million into its manufacturing site in Marietta, Pennsylvania, to double its size and capacity.
Rentschler Biopharma expands CDMO facilities in Germany
The expansion will involve the construction of a new buffer media facility and represents the largest investment from Rentschler at its Germany headquarters.
Lundbeck acquires Longboard Pharmaceuticals in $2.6 billion deal
The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.
Sanofi abandons phase 2 trial of Denali’s multiple sclerosis candidate
The big pharma company Sanofi has discontinued a phase 2 trial of U.S. partner Denali Therapeutics’ oditrasertib for the treatment of multiple sclerosis after the drug failed to perform.
Antag Therapeutics gets FDA clearance to start clinical trials with new obesity drug
The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a first-in-class treatment for obesity.
AstraZeneca licenses CSPC’s cardiovascular drug in $2 billion deal
The big pharma company AstraZeneca has forged a licensing pact worth $2 billion with the Chinese firm CSPC Pharmaceutical Group for access to an experimental small molecule treatment for dyslipidemia.
Drug discovery and bringing new medicine to market - the future of AI in pharma
Artificial intelligence (AI) is now infiltrating core industries and according to Forbes, the market is expected to reach a value of $22.6 billion dollars by next year (2025).
Insilico Medicine claims phase 2 win for AI-designed drug
The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met its primary endpoint.
AI-driven insights: SOMS boosts clinical trial success
In an in-depth conversation, OSP senior editor, Liza Laws, interviews Adrian Kizewski, associate director at IQVIA, to uncover the transformative impact of the Sub-population Optimization & Modeling Solution (SOMS) on clinical trials.
Metagenomics revolution: Empress Therapeutics on drug discovery breakthroughs
Dr Dawn Thompson has over 20 years of experience in building technology platforms that leverage genomics at scale to produce novel products.
New collaboration aims to streamline clinical trial access for patients
Global health technology company myTomorrows announced a new partnership on Tuesday (Aug 27) with Pancreatic Cancer Europe (PCE), a multi-stakeholder platform dedicated to improving care for pancreatic cancer patients.
ALZpath and Beckman Coulter partner for breakthrough diagnostic
In the ongoing battle against Alzheimer’s disease, early diagnosis is crucial.
First severe plaque psoriasis oral therapy for ages 6-17 available in the US
Amgen has announced the US availability of Otezla (apremilast) for pediatric patients aged 6 to 17 with moderate to severe plaque psoriasis.
Bavarian Nordic readies 2 million vaccine doses to fight mpox outbreak
The Danish company Bavarian Nordic plans to supply up to 2 million vaccine doses this year in response to the World Health Organization’s declaration of mpox as a Public Health Emergency of International Concern (PHEIC) earlier this month.
Rejuvenate Biomed and SAS unveil AI tool to accelerate age-related drug development
Rejuvenate Biomed and SAS have announced a creative partnership aimed at making big changes to drug discovery through the development of a user-friendly, AI-powered tool.
Women in Science - Tehmina Masud - the importance of growing outside your comfort zone
A book, a computer and some sage words from her physicist father set Tehmina on her path to a successful career in science.
Alzheimer’s Society responds to EU’s rejection of promising drug lecanemab
On Friday (July 26), the European Union’s drugs regulator, the Committee for Medicinal Products for Human Use (CHMP), advised that the drug lecanemab, a treatment for Alzheimer’s disease, should not be approved for use in the EU.
How Cure51’s AI breakthroughs are turning cancer into a manageable disease – an insider’s look
Discover the groundbreaking work of Cure51, co-founded by Nicolas Wolikow and Simon Istolainen, revolutionizing cancer treatment through advanced AI and biotechnology.
Women in science: Trailblazing neurologist Antonella Favit-VanPelt's sound advice for success
Dr. Antonella Favit-VanPelt, a distinguished neurologist, has had a lifelong passion for understanding the 'why' behind sickness, ignited by her childhood curiosity.
Roche’s oral GLP-1 receptor agonist shows promising early weight loss results in phase 1
Roche’s recent $2.7 billion acquisition of Carmot Therapeutics is paying off, with positive results for new oral GLP-1 receptor agonist.
DIA 2024
Discover how Marwan Fathallah is transforming DIA and hoping to revolutionize global healthcare
At the DIA 60th annual conference in San Diego, senior editor Liza Laws from Outsourcing Pharma had the opportunity to sit down with Marwan Fathallah, President and CEO of DIA.
How are pharmacists changing liver health management and prevention strategies?
Dr. Catherine Duggan, chief executive officer of the International Pharmaceutical Federation (FIP), has been at the helm since June 2018, based in The Hague.
Psychedelic drug investments surge in 2024: Key startups raising funds and closing deals
Psychedelic therapeutics have rapidly gained popularity in the pharma industry in a matter of just a few years. Here are five psychedelic drug discovery startups that have received investment this year.
IDT's new 25,000 sq. ft. synthetic biology facility doubles production capacity
Integrated DNA Technologies (IDT) is doubling down on its commitment to innovation with the launch of a new 25,000-square-foot synthetic biology facility in Coralville, Iowa.
Could this be the end of condoms and will men embrace the hormone-free birth control pill?
In an exclusive interview, Akash Bakshi, CEO of YourChoice Therapeutics, delves into the inspiration and journey behind developing a hormone-free birth control pill for men.
The Omentum Project - a frank and honest discussion with two time ovarian cancer survivor, Meg Wilkinson
Meg Wilkinson, a resilient cancer survivor, recently sat down with OSP editor Liza Laws to discuss her journey from diagnosis to founding the Omentum Project.
Revolutionary AI tech by Leal Health offers new hope for cancer patients - learn how
In this exclusive Q&A, Liza Laws sits down with Leal Health to discuss their groundbreaking GenAI single point of access technology.
The top 5 emerging startups fuelling drug discovery with AI
Artificial intelligence is showing great promise in the quest to unearth new drug candidates and disease targets faster than ever before.
WuXi AppTec - examining the impact of personalized medicine on reproductive health
Personalized medicine has evolved to the point where it is transforming areas of healthcare, bringing hope to patients across the world.
DIA Global 2024
AI and real-world data integration: Transforming clinical trials and drug development - panel at DIA Global
During a panel discussion held at DIA Global in San Diego this week, which was moderated by Peter Wahl, vice president and global head of scientific affairs at CorEvitas, industry experts delved into the integration of real-world data (RWD) and advanced...
IQVIA's participant payments: Streamlining clinical trial payments for global compliance
OSP recently had the opportunity to sit down with Jim DiCesare, senior director of Americas operations at IQVIA, to discuss their innovative participant payments service.
Women in Science: When you follow your passiojn for science - your capabilities will shine through
Daria Donati is chief scientific officer for Genomic Medicine at Cytiva.
Inbar Friedrich Ben-Nun on curiosity, resiliency, and the discovery of what's next.
Director of cell and gene therapy R&D at Lonza, this week's inspiring female is Inbar who we spoke to about her passion for discovering the future and mentor support sparked her early interest in biology and informed her journey of resiliency.
How is uMotif empowering clinical trials with advanced eCOA technology?
Clinical trials play a crucial role in driving medical progress, and the accurate capture of patient data is fundamental to their success.
Roquette's US innovation center marks first year of pharmaceutical advancements
As Roquette's US Innovation Center marks its first anniversary, Roquette took the opportunity to reflect on its interesting journey and achievements over the past year.
Exclusive interview: Diane Lacroix talks innovations in clinical data management
In celebration of Clinical Trials Day last month, OSP sat down with Diane Lacroix, vice president of clinical data management at eClinical Solutions, to delve into the latest advancements and future directions in clinical trials.
Interview: Has Cybin hit the biggest breakthrough in 40 years to treat psychiatric disorders?
In an intriguing interview with Cybin’s CEO, Doug Drysdale, OSP senior editor, Liza Laws found out how second-generation psychedelics could be the biggest breakthrough in psychiatry in 40 years.
UK-based company selling breakthrough cannabis-based medicines now supplying the US
UK based Celadon Pharmaceuticals Plc, that specializes in the development, production, and sale of breakthrough cannabis-based medicines, announced that it has begun shipping to the US.
What can pharma companies do to get promising antimicrobials to the frontlines of drug resistance?
A new report from Access to Medicine Foundation gives the advice to ensure the few promising antimicrobials in development reach patients on the frontlines of drug resistance.